- Home
- SGA vs LPCN Comparison
SGA vs LPCN Comparison
Compare SGA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | LPCN |
|---|---|---|
| Founded | 1986 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 61.8M |
| IPO Year | 1994 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SGA | LPCN |
|---|---|---|
| Price | $11.81 | $10.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 7.3K | ★ 79.9K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | $11,198,144.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.65 | ★ 492.80 |
| 52 Week Low | $10.68 | $2.52 |
| 52 Week High | $14.27 | $12.37 |
Technical Indicators
Market Signals| Indicator | SGA | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 62.99 |
| Support Level | $11.75 | $2.89 |
| Resistance Level | $11.99 | $10.80 |
| Average True Range (ATR) | 0.30 | 0.82 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 42.77 | 83.18 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.